These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 33948452)

  • 21. Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation.
    Bepari AK; Reza HM
    PeerJ; 2021; 9():e11261. PubMed ID: 33954055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computational assessment of select antiviral phytochemicals as potential SARS-Cov-2 main protease inhibitors: molecular dynamics guided ensemble docking and extended molecular dynamics.
    Sawant S; Patil R; Khawate M; Zambre V; Shilimkar V; Jagtap S
    In Silico Pharmacol; 2021; 9(1):44. PubMed ID: 34306960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
    Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
    J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of potential drug candidates to combat COVID-19: a structural study using the main protease (mpro) of SARS-CoV-2.
    Sharma P; Vijayan V; Pant P; Sharma M; Vikram N; Kaur P; Singh TP; Sharma S
    J Biomol Struct Dyn; 2021 Oct; 39(17):6649-6659. PubMed ID: 32741313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design.
    Meyer-Almes FJ
    Comput Biol Chem; 2020 Oct; 88():107351. PubMed ID: 32769050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease.
    Chowdhury KH; Chowdhury MR; Mahmud S; Tareq AM; Hanif NB; Banu N; Reza ASMA; Emran TB; Simal-Gandara J
    Biology (Basel); 2020 Dec; 10(1):. PubMed ID: 33374717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Re-purposing of hepatitis C virus FDA approved direct acting antivirals as potential SARS-CoV-2 protease inhibitors.
    Uddin R; Jalal K; Khan K; Ul-Haq Z
    J Mol Struct; 2022 Feb; 1250():131920. PubMed ID: 34815586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined drug repurposing and virtual screening strategies with molecular dynamics simulation identified potent inhibitors for SARS-CoV-2 main protease (3CLpro).
    Khan A; Ali SS; Khan MT; Saleem S; Ali A; Suleman M; Babar Z; Shafiq A; Khan M; Wei DQ
    J Biomol Struct Dyn; 2021 Aug; 39(13):4659-4670. PubMed ID: 32552361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking.
    Mohapatra S; Nath P; Chatterjee M; Das N; Kalita D; Roy P; Satapathi S
    PLoS One; 2020; 15(11):e0241543. PubMed ID: 33180803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents.
    Ahmed MZ; Zia Q; Haque A; Alqahtani AS; Almarfadi OM; Banawas S; Alqahtani MS; Ameta KL; Haque S
    J Infect Public Health; 2021 May; 14(5):611-619. PubMed ID: 33866129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
    Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
    J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease.
    Balakrishnan V; Lakshminarayanan K
    Int J Pept Res Ther; 2021; 27(1):651-658. PubMed ID: 33013255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Facilitating SARS CoV-2 RNA-Dependent RNA polymerase (RdRp) drug discovery by the aid of HCV NS5B palm subdomain binders: In silico approaches and benchmarking.
    Elghoneimy LK; Ismail MI; Boeckler FM; Azzazy HME; Ibrahim TM
    Comput Biol Med; 2021 Jul; 134():104468. PubMed ID: 34015671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
    Choudhary S; Malik YS; Tomar S
    Front Immunol; 2020; 11():1664. PubMed ID: 32754161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease.
    Khater I; Nassar A
    Biochem Biophys Rep; 2021 Sep; 27():101032. PubMed ID: 34099985
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
    Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
    Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A molecular docking study of SARS-CoV-2 main protease against phytochemicals of
    Rutwick Surya U; Praveen N
    Virusdisease; 2021 Mar; 32(1):46-54. PubMed ID: 33758772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.